Percentage of patients, regardless of age, with a diagnosis of prostate cancer at high or very high risk of recurrence receiving external beam radiotherapy to the prostate who were prescribed androgen deprivation therapy in combination with external beam radiotherapy to the prostate.
This measure is to be submitted once per episode of radiation therapy for all male patients with prostate cancer who receive external beam radiotherapy to the prostate during the performance period. Each episode of radiation therapy in an eligible patient receiving external beam radiotherapy to the prostate occurring during the performance period will be counted when calculating the data completeness and performance rates. The quality data code or equivalent needs to be submitted only once during the episode of radiation therapy (e.g., 8 weeks of therapy). It is anticipated that Merit-based Incentive Payment System (MIPS) eligible clinicians who perform external beam radiotherapy to the prostate will submit this measure.
Measure Submission Type:
Measure data may be submitted by individual MIPS eligible clinicians, groups, or third party intermediaries. The listed denominator criteria are used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions as allowed by the measure. The quality data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third party intermediaries that utilize this modality for submissions; however, these codes may be submitted for those third party intermediaries that utilize Medicare Part B claims data. For more information regarding Application Programming Interface (API), please refer to the Quality Payment Program (QPP) website.
All patients, regardless of age, with a diagnosis of prostate cancer at high or very high risk of recurrence receiving external beam radiotherapy to the prostate
Risk Strata - Very Low, Low, Intermediate, High, or Very High –
Very Low Risk – PSA < 10 ng/mL; AND Gleason score 6 or less/Gleason grade group 1; AND clinical stage T1c; AND presence of disease in fewer than 3 biopsy cores; AND ≤ 50% prostate cancer involvement in any core; AND PSA density < 0.15 ng/mL/cm3.
Low Risk – PSA < 10 ng/mL; AND Gleason score 6/Gleason grade group 1; AND clinical stage T1 to T2a.
Intermediate Risk – PSA 10 to 20 ng/mL; OR Gleason score 7/Gleason grade group 2-3; OR clinical stage T2b to T2c.
Note: Patients with multiple adverse factors may be shifted into the high risk category
High Risk – PSA > 20 ng/mL; OR Gleason score 8 to 10/Gleason grade group 4-5; OR clinically localized stage T3a.
Note: Patients with multiple adverse factors may be shifted into the very high risk category.
Very High Risk – Clinical stage T3b to T4; OR primary Gleason pattern 5; OR more than 4 cores with Gleason score 8 to 10/Gleason grade group 4-5. (NCCN, 2017)
External beam radiotherapy – “External beam radiotherapy” refers to 3D conformal radiation therapy (3D- CRT), intensity modulated radiation therapy (IMRT), stereotactic body radiotherapy (SBRT), and proton beam therapy.
Denominator Criteria (Eligible Cases):
Any male patient, regardless of age
Diagnosis for prostate cancer (ICD-10-CM): C61
AND Patient encounter during the performance period (CPT): 77427, 77435
Telehealth Modifier: GQ, GT, 95, POS 02
High or very high risk of recurrence of prostate cancer: G8465
Diagnosis for metastatic cancer (ICD-10-CM): C77.0, C77.1, C77.2, C77.3, C77.4, C77.5, C77.8, C77.9, C78.00, C78.01, C78.02, C78.1, C78.2, C78.30, C78.39, C78.4, C78.5, C78.6, C78.7, C78.80, C78.89, C79.00, C79.01, C79.02, C79.10, C79.11, C79.19, C79.2, C79.31, C79.32, C79.40, C79.49, C79.51, C79.52, C79.60, C79.61, C79.62, C79.63, C79.70, C79.71, C79.72, C79.81, C79.82, C79.89, C79.9
Patients who were prescribed androgen deprivation therapy in combination with external beam radiotherapy to the prostate
Prescribed – Includes patients who are currently receiving medication(s) that follow the treatment plan recommended at an encounter during the performance period, even if the prescription for that medication was ordered prior to the encounter.
NUMERATOR NOTE: Denominator Exception(s) are determined on the date of the denominator eligible encounter
Performance Met: Androgen deprivation therapy prescribed/administered in combination with external beam radiotherapy to the prostate (G9894)
Denominator Exception: Documentation of medical reason(s) for not prescribing/administering androgen deprivation therapy in combination with external beam radiotherapy to the prostate (e.g., salvage therapy) (G9895)
Denominator Exception: Documentation of patient reason(s) for not prescribing/administering androgen deprivation therapy in combination with external beam radiotherapy to the prostate (G9896)
Performance Not Met: Patients who were not prescribed/administered androgen deprivation therapy in combination with external beam radiotherapy to the prostate, reason not given (G9897)
The use of androgen deprivation therapy in combination with external beam radiotherapy is a well-established standard of care for high-risk prostate cancer patients. Multiple large studies have shown that men who receive androgen deprivation therapy in combination with external beam radiation therapy can live longer and have a lower risk of recurrence than men who receive radiation therapy alone. In addition, a cost-analysis conducted found that the use of androgen deprivation therapy and external beam radiation therapy is cost-effective and adds quality-adjusted life years for patients (Satish et al., 2006).
Data from several sources indicates that while utilization rates of androgen deprivation therapy and external beam radiation therapy have increased, they still remain suboptimal. One study analyzing the CaPSURE database, a provider-based registry, found that the utilization of androgen deprivation therapy and external beam radiation therapy for high-risk patients has increased to 80% throughout the past two decades, yet utilization rates have plateaued since 2000 (Cooperberg et al., 2008). There is rising concern about undertreatment of high-risk prostate cancer patients (Cooperberg, Broering, Caroll, 2010). This suggests greater outreach and education are needed to improve outcomes in care.
Clinical Recommendation Statements
Clinicians should recommend radical prostatectomy or radiotherapy plus androgen deprivation therapy as standard treatment options for patients with high-risk localized prostate cancer. (Strong Recommendation; Evidence Level: Grade A) (AUA/ASTRO/SUO, 2017)
Men with prostate cancer that is clinical stage T3a, Gleason score 8 to 10/Gleason grade group 4-5, or PSA level greater than 20 ng/mL are categorized by the panel as high risk. Patients with multiple adverse factors may be shifted to the very high-risk category. [See detailed risk strata above]. The preferred treatment is EBRT [external beam radiation therapy] in conjunction with 2 to 3 years of neoadjuvant/concurrent/adjuvant ADT [androgen deprivation therapy] (category 1); ADT alone is insufficient. In particular, patients with low-volume, high-grade tumor warrant aggressive local radiation combined with typically 2 or 3 years of neoadjuvant/concurrent/adjuvant ADT. Fit men in the high-risk group can consider 6 cycles of docetaxel without prednisone after EBRT is completed and while continuing ADT. The combination of EBRT and brachytherapy, with or without neoadjuvant/concurrent/adjuvant ADT, is another primary treatment option. However, the optimal duration of ADT in this setting remains unclear. (NCCN, 2017)
Patients at very high risk (locally advanced) are defined by the NCCN Guidelines as men with clinical stages T3b to T4, primary Gleason pattern 5, or more than 4 biopsy cores with Gleason score 8 to 10/Gleason grade group 4-5. The options for this group include: 1) EBRT and long-term ADT (category 1); 2) EBRT plus brachytherapy with or without long-term ADT; 3) radical prostatectomy plus PLND in younger, healthier patients with no tumor fixation to the pelvic side wall; or 4) ADT or observation for patients not candidates for definitive therapy. (NCCN,2017)